About Ciliary-associated calcium-binding coiled-coil protein 1
Ciliary-associated calcium-binding coiled-coil protein 1 (CABCOCO1) is a protein
from Homo sapiens identified by UniProt accession
Q8IVU9, 208 residues long.
MolForge cross-references it against 0 known binders and
144 disease associations.
Target properties
| Protein name | Ciliary-associated calcium-binding coiled-coil protein 1 |
|---|
| UniProt accession | Q8IVU9 |
|---|
| Gene | CABCOCO1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 208 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (144)
Diseases linked to this target (Open Targets).
- systolic blood pressure · score 0.52
- diastolic blood pressure · score 0.52
- mean arterial pressure · score 0.49
- hypertension · score 0.48
- alcohol drinking · score 0.48
- smoking status measurement · score 0.48
- Beta blocking agent use measurement · score 0.41
- Agents acting on the renin-angiotensin system use measurement · score 0.41
- alcohol consumption measurement · score 0.41
- Diuretic use measurement · score 0.41
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8IVU9-F1 | alphafold | PREDICTED | 77.31 | — |
Amino-acid sequence (208 residues)
MDFSIIQYSK FMTLLAMSLQ NLKTLHMSLE ESIKWLGEVM AEIGPTHSQK SEDWNIFDVK QANAIIDYLK ISLFQHYKLY EFMFYSAREE IVIGTEQVIE VVKSACGPFP NPLEEGISFD IYSTFIEPPT ILDTEMKRLD QEQGPEESQP ETDTSDMDPL VGFTIEDVKS VLDQVTDDIL IGIQTEINEK LQIQEEAFNA RIEKLKKA
Explore Ciliary-associated calcium-binding coiled-coil protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets